Are you attending AAPS NERDG 2025 Annual Meeting in Connecticut? Stop by our booth to chat with Sr. Director Daniel J. O'Connor, Sr. about what’s included in the upcoming release of GPX.2. https://lnkd.in/g4EJKf4D
Simulations Plus, Inc.
软件开发
Lancaster,California 10,725 位关注者
Where are you in the drug development process? Save resources & get to market faster with our solutions!
关于我们
Simulations Plus is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI) and machine learning (ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, and consumer goods companies, and regulatory agencies worldwide. For more information visit us at www.simulations-plus.com
- 网站
-
https://www.simulations-plus.com
Simulations Plus, Inc.的外部链接
- 所属行业
- 软件开发
- 规模
- 201-500 人
- 总部
- Lancaster,California
- 类型
- 上市公司
- 创立
- 1996
- 领域
- Modeling & Simulation Software and Consulting Services、ADME-Tox Screening, Data Mining, Library Design、PBPK/PD Modeling & IVIVCs、Drug-Drug Interactions & Virtual Population Trials、Nonlinear Metabolism/Transport &Metabolite Tracking、PK/PD Modeling and Simulation、PBPK Modeling & Simulation、Drug Development、Regulatory Writing、Quantitative Systems Pharmacology、Clinical Pharmacology、Model-based Drug Discovery & Development、ADMET Property Estimation、QSAR Modeling & Analysis、QSP/QST modeling、On-site Training、Quantitative Systems Toxicology、End-to-End in silico solutions、Pharmacometrics、NCA PK Reporting、Compartmental PK Reporting、Drug-Induced-Liver-Injury 、Cloud-based Web Application KIWI、Non-Alcholic Fatty Liver Disease、in vitro Dissolution Method Design、in vitro Permeability、FREE Chemical Sketching Software和PBTK Modeling & Analysis/Simulation
地点
-
主要
42505 10th Street West
Suite 103
US,California,Lancaster,93534
Simulations Plus, Inc.员工
-
Sharlene Evans
-
Daniel J. O'Connor, Sr.
Partnering with clients to provide data-driven, strategic modeling methodology that streamlines success!
-
John K. Paglia, Ph.D., CFA, CPA
-
John DiBella
Partnering with clients to provide a data-driven, strategic modeling methodology that streamlines success.
动态
-
Identifying potential DILI risk remains a critical challenge for drug development researchers. In a new article currently in pre-press, the authors review pre-clinical, in silico, and clinical development approaches to screen for DILI potential. DILIsym? was the only quantitative systems toxicology (QST) modeling solution included in the assessment, and was noted to be the “most widely used QST modelling software for DILI prediction.” Of particular note is a table within the publication describing the types of nonclinical data assessed by the DILI team at the US FDA. DILIsym is included as a source of QST modeling-based data that is assessed by the FDA’s DILI team. Read more about current and effective tools for DILI risk assessment: https://lnkd.in/g7H3hB4J
-
-
Are you planning to attend the annual ASPET conference in Portland, Oregon? Add this pre-conference workshop to your agenda,“PBPK/PD Modeling: Hands-on Workshop for Drug Development Applications.”? You will learn to build, validate, and apply PBPK/PD models through expert demonstrations and interactive exercises. The workshop aims to enhance attendees’ ability to use PBPK/PD modeling in their research for data-driven decision-making.? https://lnkd.in/gkzucR2d
-
Are you attending PAGE 2025 Meeting in Thessaloniki, Greece? Enhance your skills with expert-led training in pharmacometrics modeling, simulations, and workflow automation. Workshops we're hosting: - Introductory Course for Pharmacometrics Modeling using Monolix?: Learn the essentials of population modeling—no prior experience required! - Advanced Course for Pharmacometrics Modeling using Monolix?: Dive deep into complex models and advanced strategies for expert-level insights. - From Simple to Complex Simulations in Pharmacometrics using Simulx?: Master pharmacometric simulations, from basics to advanced clinical trial scenarios. - Automating Pharmacometrics Workflows: Scripting using lixoftConnectors: Discover R-API functions to automate MonolixSuite workflows and improve project efficiency. Register for one 1.5-day workshop + one half-day workshop and receive a 50% discount on the shorter course! Enhance your skills—register today! https://lnkd.in/gzAVUUky
-
Are you at the SOT 64th Annual Meeting & ToxExpo? Make sure to stop by booth #1327 to ask, Senior Principal Scientist, Michael Lawless about his poster presentation, “Clustering of environmental compounds based on structure and toxicokinetic properties." https://lnkd.in/gmX-92fN
-
-
In a fast-paced industry with big budget competition, you need every tool and approach to succeed. This is the first installment in our 4-part Biotech Webinar Series. In this series, our experts will walk you through the development stages of an obesity drug, showcasing how AI-powered tools and modeling & simulation software can shorten the development timeline while increasing confidence in a compound’s efficacy and safety. They’ll demonstrate how to address common challenges with obesity (and other) drugs, such as identifying optimal dosing paradigms and minimizing gastrointestinal adverse events. You’ll learn how AI-powered tools and modeling & simulation can help you… ? Accelerate the design & optimization of your drug candidates while prioritizing them based on potential hazards like DILI risk ? Determine the right dosing paradigms in as few iterations as possible ? Set up a clinical development plan to increase likelihood of acquisition and/or out-licensing ? Optimize your clinical trial protocol and training ? And more In this session, Drs. Jeremy Jones and Scott Siler will introduce some of the common challenges in developing drugs targeting obesity. They will then dive into how AI-driven design and mechanistic modeling can shorten the discovery timeline while increasing confidence in the drug candidates selected for development. Register now to secure your spot! https://lnkd.in/gXUvSw8q
-
Researchers latest analysis from the AVERT-2 study (Assessing Very Early Rheumatoid Arthritis Treatment-2) investigates the relationship between serum exposure to subcutaneous (SC) abatacept and infection risk in adult patients with early RA. Curious about what this means for RA treatment and patient safety? Read more here: https://lnkd.in/gY5qNrAH
-
-
Will you be at the 14th??Annual Indiana CTSI Pharmacometrics Modeling and Simulation Symposium? We will! You won’t want to miss the presentation from Haiying Zhou, Executive Director, PBPK R&D at Simulations Plus—she’ll be speaking on March 19 about the application of PBPK modeling to support FIH predictions for non-small molecules. Details: https://lnkd.in/gMq2xVNh
-